Acarbose/metformin

Drug Profile

Acarbose/metformin

Alternative Names: BAY81-9783; Glucobay-M; Metformin/acarbose

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors; AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in South Korea (PO, Tablet)
  • 31 Dec 2012 Bayer completes a phase I trial in healthy volunteers in South Korea (NCT01728740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top